Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Link
http://www.nature.com/articles/leu2013296.pdf
Reference17 articles.
1. Vannucchi AM, Guglielmelli P, Tefferi A . Advances in under standing and management of myeloproliferative neoplasms. CA Cancer J Clin 2009; 59: 171–191.
2. Barosi G, Magrini U, Gale RP . Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis? Leuk Res 2010; 34: 1119–1120.
3. Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR . Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010; 95: 1216–1220.
4. Pardanani A . Ruxolitinib for myelofibrosis therapy:current context, pros and cons. Leukemia 2012; 26: 1449–1451.
5. Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012; 5: 552.
Cited by 62 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN);Annals of Hematology;2024-07-05
2. Acute invasive fungal sinusitis with orbital tip syndrome in patients on long-term use of ruxolitinib: a case report;Journal of Medical Case Reports;2024-04-05
3. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis;Bone Marrow Transplantation;2024-02-24
4. Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers;Cancer Drug Resistance;2024-01-12
5. Treatment of steroid-refractory graft versus host disease in children;Frontiers in Transplantation;2023-09-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3